Christopher B. Ehrlich

Christopher B. Ehrlich

CEO and Secretary at Phoenix Biotech Acquisition Corp.

Are you Christopher B. Ehrlich? Claim your profile
  • IDENTIFY executive and board member connections in Christopher B. Ehrlich's network.
  • FOLLOW changes in Christopher B. Ehrlich's employment.
  • CONNECT with Christopher B. Ehrlich through your network of contacts.

Christopher B. Ehrlich's Executive Work History

CEO and Secretary,
CEO and Secretary
Equilar on 10/12/2021
Phoenix Biotech Acquisition Corp.
Board Member,
Board Member
eFFECTOR Therapeutics, Inc. DEF 14A on 04/20/2022
eFFECTOR Therapeutics, Inc.
To view Christopher B. Ehrlich's complete executive work history,
B.A., Dartmouth College

Christopher B. Ehrlich's Biography

Chris Ehrlich served as LWAC's Chief Executive Officer and Director from October 2020 to August 2021 and continues to serve on the Board following the Business Combination. Mr. Ehrlich has served as Chief Executive Officer of Phoenix Biotech Acquisition Corp. since October 2021. Mr. Ehrlich served in various roles at Locust Walk Partners starting in 2013, first as Senior Managing Director and Head of Locust Walk Partners' Global Biopharma team until 2021, and beginning in 2021 as Chief Executive Officer of Locust Walk Acquisition Corp. Prior to joining Locust Walk Partners in 2013, Mr. Ehrlich served as a Managing Director at InterWest Partners, a venture capital firm focused on healthcare and information technology, from 2000 to 2013. At InterWest, he served on the boards of KAI Pharmaceuticals, a privately held pharmaceutical company(acquired by Amgen in 2012), Biomimetic Therapeutics, Inc., a biotechnology company (acquired by Wright Medical Technologies in 2013), Invuity, Inc., a medical technology company acquired by Stryker in 2018) and Xenon Pharmaceuticals, a biopharmaceutical company (NASDAQ:XENE). Prior to joining InterWest, Mr. Ehrlich was the Director of Licensing and Business Development at Purdue Pharma, a private pharmaceutical firm, where he was responsible for developing a biologic oncology franchise, including in-licensing key intellectual properties, establishing and managing collaborations with biotechnology companies and leading the commercial operations of Purdue BioPharma, a biotechnology company. Prior to joining Purdue BioPharma, Mr. Ehrlich worked in business development at Genentech, a biotechnology company, in venture capital at the U.S. Russia Investment Fund, and in biotechnology strategy development at L.E.K. Consulting. Since 2014, Mr. Ehrlich has served on the board of directors of Prostate Management Diagnostics, Inc., a diagnostics company, on the Advisory Board of the Peter Michael Foundation, a charity focused on prostate cancer where he has been a Senior Advisor since 2012, and on the Healthcare at Kellogg Advisory Board at Northwestern University since 2019. He received his undergraduate degree from Dartmouth College and a MBA from the Kellogg School of Management at Northwestern University. He is also a registered representative with FINRA, holding his Series 79, 63 and 24 licenses. Mr. Ehrlich's extensive experience in the biotechnology industry generally, as well as extensive experience in venture capital and business development, contributed to our Board's conclusion that he should serve as a director of our Company.

Source: eFFECTOR Therapeutics, Inc. on 04/20/2022


By accessing ExecAtlas, you can view bios, network, connections and references of industry leading executives like Christopher B. Ehrlich. More specifically, you'll be able to:

  • IDENTIFY executive and board member connections in Christopher B. Ehrlich's network.
  • FOLLOW changes in Christopher B. Ehrlich's employment.
  • CONNECT with Christopher B. Ehrlich through your network of contacts.

Access over 1,500,000 executive and board member profiles.

Example: Christopher B. Ehrlich

Christopher B. Ehrlich's Connections (68)

Earl Martin Douglas
Former Vice President and General Counsel, BioMimetic Therapeutics
Russell P. Pagano Ph.D.
Vice President, Quality and Regulatory Affairs, ENABLE INJECTIONS, INC
Douglas J Warner
Chief Medical Officer, eFFECTOR Therapeutics, Inc.
Premal Patel M.D., Ph.D.
Advisor, Fanconi Anemia Research Fund Inc
Brian G. Atwood
Board Member, Clovis Oncology, Inc.
Ann F. Hanham Ph.D.
Chairman, HTG Molecular Diagnostics, Inc.
Leone D. Patterson
Chief Financial and Business Officer, Tenaya Therapeutics, Inc.
Matthew M. Loar
Former Chief Financial Officer, Osteologix Holdings
Jennifer A. Doudna Ph.D.
Co-founder, Scientific Advisor, Scribe Therapeutics, Inc.
Mark Densel
Vice President, Development Operations, eFFECTOR Therapeutics, Inc.